159 related articles for article (PubMed ID: 17460705)
21. Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series.
Coutinho R; Costa D; Carrió A; Muñoz C; Vidal A; Belkaid M; Campo E; Nomdedeu B
Ann Hematol; 2010 Oct; 89(10):1069-70. PubMed ID: 20232065
[No Abstract] [Full Text] [Related]
22. Lenalidomide-induced durable hematological and cytogenetic remission in del(5q)-associated de novo acute myeloid leukemia.
Hussein K; Tefferi A
Leuk Res; 2009 Aug; 33(8):e132-3. PubMed ID: 19304324
[No Abstract] [Full Text] [Related]
23. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.
Adès L; Eclache V; Gardin C; Boehrer S; Leroux G; Martiat P; Fenaux P
Bone Marrow Transplant; 2010 Apr; 45(4):791-2. PubMed ID: 19718061
[No Abstract] [Full Text] [Related]
25. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Tefferi A; Cortes J; Verstovsek S; Mesa RA; Thomas D; Lasho TL; Hogan WJ; Litzow MR; Allred JB; Jones D; Byrne C; Zeldis JB; Ketterling RP; McClure RF; Giles F; Kantarjian HM
Blood; 2006 Aug; 108(4):1158-64. PubMed ID: 16609064
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide induces remission and mixed quantitative chimerism fluctuations in refractory and relapsed myeloid malignancy with del (5).
Dumas PY; Pigneux A; Tabrizi R; Milpied N
Leuk Res; 2010 Nov; 34(11):e302-3. PubMed ID: 20650527
[No Abstract] [Full Text] [Related]
28. Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
Basile FG
Leuk Lymphoma; 2009 Apr; 50(4):653-5. PubMed ID: 19373666
[No Abstract] [Full Text] [Related]
29. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
[TBL] [Abstract][Full Text] [Related]
30. Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases.
Himmelmann A; Tchinda J
Leuk Res; 2012 May; 36(5):656-7. PubMed ID: 22177945
[No Abstract] [Full Text] [Related]
31. [Molecular mechanisms of lenalidomide for the treatment of myelodysplastic syndromes].
Katayama Y
Rinsho Ketsueki; 2011 Jul; 52(7):447-51. PubMed ID: 21821975
[No Abstract] [Full Text] [Related]
32. Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
Göhring G; Lange K; Hofmann W; Nielsen KV; Hellström-Lindberg E; Roy L; Morgan M; Kreipe H; Büsche G; Giagounidis A; Schlegelberger B
Leukemia; 2012 Feb; 26(2):356-8. PubMed ID: 21799512
[No Abstract] [Full Text] [Related]
33. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
34. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
[TBL] [Abstract][Full Text] [Related]
35. JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib.
Koehler A; Hubert K; Lange T; Siebolts U; Wickenhauser C; Gopalakrishna P; Niederwieser D; Monecke A; Al-Ali HK
Ann Hematol; 2015 Nov; 94(11):1929-30. PubMed ID: 26202608
[No Abstract] [Full Text] [Related]
36. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Rosillo C; Camoriano JK
Am J Hematol; 2007 May; 82(5):400-2. PubMed ID: 17133423
[TBL] [Abstract][Full Text] [Related]
37. Idiopathic myelofibrosis and pyoderma gangrenosum involving a mutation of Janus kinase 2 (JAK2V617F), showing poor prognosis.
Hideki M; Tetsurou T; Sakae F; Kensei K; Makoto O; Toshinobu K
Eur J Dermatol; 2013 Apr; 23(2):256-7. PubMed ID: 23557850
[No Abstract] [Full Text] [Related]
38. Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide.
Zou YS; Fink SR; Stockero KJ; Paternoster SF; Smoley SA; Tun HW; Reeder CB; Tefferi A; Dewald GW
Leuk Res; 2007 Sep; 31(9):1185-9. PubMed ID: 17125835
[TBL] [Abstract][Full Text] [Related]
39. Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
Dasanu CA; Schwartz RA; Bauer F; Davis LK; Silver JS; Reale MA
Leuk Res; 2011 May; 35(5):e41-3. PubMed ID: 21288571
[No Abstract] [Full Text] [Related]
40. Isoderivative of deleted chromosome 20 in primary myelofibrosis (PMF) characterized by molecular cytogenetics and array CGH.
Douet-Guilbert N; Andrieux J; Laï JL; Morice P; Demory JL; Basinko A; Ugo V; Gueganic N; Le Bris MJ; Morel F; De Braekeleer M
Ann Hematol; 2009 Nov; 88(11):1157-9. PubMed ID: 19444446
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
